Assessment of Private Sector ART Centres in Delhi NCR – *A Descriptive Study*

Mentor: Sandesh Sharma

Student: Kingshuk Mazumder, MBA HM27, 1530

A Brief History, Mission, Vision

Alliance India is a non-governmental organisation, founded in 1999. It works in the field of HIV/AIDS, and implements the policies and guidelines framed by the National AIDS Control Organization (NACO). The work of Alliance India complements the Indian government's national programme on HIV/AIDS.

It operates in partnership with civil society, government and communities to support sustained responses to HIV in India that protect rights and improve health.

Mission – To support community action to prevent HIV infection, meet the challenges of AIDS, and build healthier communities.

Vision – A world in which no one dies of AIDS.

Sl. No	Indiactor	Numerator	Denominator	Indicator Score		
Section 1] ART Care - New PLHIV (Financial Year) - (20)						
1	Proportion of PI.HIV initiated on ART out of those who are registered in current FY	PI.HIV initiated on ART	PI.HIV registered in HIV Care during the current financial year (April - reporting month)	0 to 84.9%	85% to 96.9%	97% and above
2	Proportion of PI.HIV who became LFU, MIS 2, MIS 3 and opted out, out of those initiated on ART in FY	PI.HIV whose status is LFU, MIS 2, MIS 3 and opted out	PI.HIV initiated on ART in the current financial year (April - reporting month)	6.1% and above	3.1% to 6%	0 to 3%
3	Proportion of PI.HIV who died out of those initiated on ART in FY	PI.HIV reported died	PI.HIV initiated on ART in the current financial year (April - reporting month)	5.1% and above	2.1% to 5%	0 to 2%
Section 2] Overall ART Care and Retention (25)						
4	Proportion of PI.HIV on MMD (3 Months) out of alive on ART at the end of the reporting quarter	PI.HIV on MMD (3 month dispensation) out of PI.HIV on ART	PI.HIV alive on ART	0 to 44.9%	45% to 59.9%	60% and above
5	Proportion of PI.HIV on ART retained at the end of the reporting quarter	PI.HIV on ART at the end of the reporting quarter.	PI.HIV Alive on ART (excluding MIS 2 and MIS 3) at the end of the previous quarter; Plus PI.HIV newly initiated on ART, tracked back and transferred in; and minus transferred out during the reporting quarter	0 to 96.9%	97% to 98.4%	98.5% and above
6	Proportion of PI.HIV who are reported MIS 2, MIS 3, LFU and opted out during the reporting quarter.	PI.HIV who are reported MIS 2, MIS 3, LFU and opted out during the reporting quarter.	PI.HIV alive on ART (excluding MIS 2 and MIS 3) at the end of the previous quarter; Plus PI.HIV newly initiated on ART, tracked back and transferred in; and minus transferred out during the reporting quarter	2.1% and above	1.1% to 2%	0 to 1%

Section 3] Viral load coverage and suppression (20)							
7	Proportion of PI.HIV on ART with a VL result documented within the past 12 months out of those who have completed six month of ART at the end of the reporting quarter.	PI.HIV on ART with a VL result documented within the past 12 months.	PI.HIV alive and on ART eligible for VL testing (PI.HIV those who have completed six-month on ART) at the end of the reporting quarter.	0 to 59.9%	60% to 79.9%	80% and above
8	Proportion of PI.HIV on ART with suppressed Viral load (based on latest result) out of those with a VL result documented within the last 12 months.	PI.HIV on ART with suppressed Viral load (based on latest result) within the last 12 months	PI.HIV on ART with a VL result documented within the last 12 months.	0 to 89.9%	90% to 94%	95% and above
Section 4] HIV-TB prevention & care (15)							
9	Proportion of PI.HIV tested for TB out of those identified as presumptive TB during the reporting quarter	PI.HIV tested for TB	PI.HIV identified as presumptive TB during the reporting quarter	0 to 94.9%	95% to 99.9%	100%
10	Proportion of PI.HIV initiated on ART out of those diagnosed with TB during the current FY	PI.HIV initiated on ART	Co-infected patients enrolled in HIV/TB register during the current financial year (April till reporting month)	0 to 84.9%	85% to 96.9%	97% and above
11	Proportion of PI.HIV started TPT out of those eligible at the end of the reporting quarter.	PI.HIV started TPT	PI.HIV eligible for TPT at the end of the reporting quarter.	0 to 69.9%	70% to 84.9%	85% and above
12	Proportion of PI.HIV completed TPT during the quarter	PI.HIV completed TPT during the quarter	PI.HIV started on TPT six months prior (two quarter back)	0 to 69.9%	70% to 84.9%	85% and above

Section 5] Second line and third line cascade (Viral load result utilisation) - (15)							
13	Proportion of PI.HIV with unsuppressed VL result (in the last quarter) undergone repeat VL testing by the end of the reporting quarter.	PI.HIV with unsuppressed VL result (in the last quarter) undergone repeat VL testing by the end of the reporting quarter.	PI.HIV who were unsuppressed as per first VL test in last quarter.	0 to 89.9%	90% to 94.9%	95% and above
14	Proportion of PI.HIV referred to SACEP, of those who are virally unsuppressed as per the repeat VL test during the reporting quarter	PI.HIV referred to SACEP, of those who are virally unsuppressed as per the repeat VL test during the reporting quarter	"PI.HIV who are virally unsuppressed as per the repeat VL test during the reporting quarter"	0 to 89.9%	90% to 94.9%	95% and above
15	Proportion of PI.HIV switched to second line or third line of those recommended by SACEP during current FY	PI.HIV switched to second line or third line, of those recommended by SACEP during current FY	PI.HIV recommended for switch (second line or third line) after review by SACEP during the current FY (April – reporting month).	0 to 79.9%	80% to 94.9%	95% and above
Section 6] Data Quality (5)							
16	Proportion of mismatch between MPR and SOCH data	Variance between PI.HIV on ART reported in SOCH and MPR	Total number of PI.HIV alive & on ART as per SOCH	5.1% and above	0.1% to 5 %	0%	

Period		1st Q	Indicator													
		2022-	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
SN	ART		% PLHIV initiated on ART out of those who are registered in current FY	% PLHIV who became LFU, MIS 2, MIS 3 and opted out, out of those initiated on ART in FY	% PLHIV who died out of those initiated on ART in FY	% PLHIV on MMD (3 Months) out of alive on ART at the end of the reporting quarter	% PLHIV on ART retained at the end of the reporting quarter	% PLHIV who are reported MIS 2, MIS 3, LFU and opted out during the reporting quarter	% PLHIV who are virally unsuppressed as per the repeat VL test within the past 12 months out of those who have completed six month of ART at the end of the reporting quarter	% PLHIV on ART with suppressed Viral load (based on latest result) out of those with a VL result documented within the last 12 months	% PLHIV tested for TB out of those identified as presumptive TB during the reporting quarter	% PLHIV initiated on ART out of those diagnosed with TB during the current FY	% PLHIV started TPT out of those eligible at the end of the reporting quarter.	% PLHIV Completed TPT during the quarter	% PLHIV with unsuppressed viral load result(in the last quarter), undergone repeat viral load testing by the end of the reporting quarter	% PLHIV referred to SACEP of those who are virally unsuppressed as per the repeat VL test during the reporting quarter	% PLHIV switched to second line or third line of those recommended by SACEP during the current financial yr
Performance of S ARTs in Q-1																	
1 BP Civil Hospita	Nagaon	Assm															
2 GMCH	Kamrup	Assm															
3 Duncan Hospita	East Chant	Bihar	100	0	0	0	100	0	32	97	100	75	0	0	67	0	0
4 DMCH	Darbhang	Bihar	94	0	0	73	97	4	11	90	72	86	9	69	58	0	0
5 SH, Motihari	East Chant	Bihar	100	5	2	76	107	9	9	85	66	100	37	36	84	31	0
6 JLNMCH	Bhagalpur	Bihar	99	0	4	77	100	14	57	84	21	96	0	0	60	100	100
7 LBS Hospital	Delhi	Delhi															
8 DDU Hospital	Delhi	Delhi															
9 GTB Hospital	Delhi	Delhi															
10 SSG Hospital	Vadodara	Guj	86	4	8	0	100	2	93	93	100	96	46	70	17	100	100
11 Sir T General H	Bhavnagar	Guj	93	11	7	13	100	0	79	95	100	95	48	78	13	37	100
12 Sadar Hospital	Koderma	Jhar	100	0	0	0	97	4	19	77	100	100	91	100	80	38	100
13 RIMS	Ranchi	Jhark	87	0	0	15	95	2	44	35	100	71	86	69	100	100	100
14 Hassan	Hassan	KA	94	3	2	1	99	7	97	76	96	100	0	0	83	0	100

Learnings and Value Additions

Objective of the study: NACO has identified key indicators to gauge the performance of each ART centre, and developed a score card to objectively assess the performance of each site and provide needed feedback to the State AIDS Control Society (SACS).

Methodology:

Sampling Technique: Convenient Sampling Technique.

Duration of study: 12 months (FY 2022-23).

Sample size: 2 ART Centres.

Data collection method: Secondary Data recorded through assessment visits.

Name of ART & Code		ART Centre, GTB Hospital, New Delhi											Year		2022-23
District		New Delhi													
	Perfomance Indicators	April-June-22		%	July-Sep 22		%	Oct-Dec 22		%	Jan-March-23		%		
		D	N		D	N		D	N		D	N			
1	PLHIV initiated on ART out of those who are registered in current FY	266	245	92	502	475	95	688	654	95	814	782	96		
2	PLHIV who became LFU, MIS 2, MIS 3 and opted out, out of those initiated on ART in FY	245	18	7	475	152	32	654	77	12	782	118	15		
3	PLHIV who died out of those initiated on ART in FY	245	3	1	475	6	1	654	12	2	782	24	3		
4	PLHIV on MMD (3 Months) out of alive on ART at the end of the reporting quarter	4552	32	1	4754	185	4	4885	51	1	4922	49	1		
5	PLHIV on ART retained at the end of the reporting quarter	6233	4552	73	6492	4754	73	6783	4885	72	6786	4922	73		
6	PLHIV who are reported MIS 2, MIS 3, LFU and opted out during the reporting quarter.	6233	1920	31	6492	2003	31	6783	1949	29	6786	1917	28		

Name of ART & Code		ART Centre, LBS Hospital, New Delhi											Year		2022-23
District		New Delhi													
	Perfomance Indicators	April-June-22		%	July-Sep 22		%	Oct-Dec 22		%	Jan-March-23		%		
		D	N		D	N		D	N		D	N			
1	PLHIV initiated on ART out of those who are registered in current FY	114	107	94	235	228	97	317	306	97	380	368	97		
2	PLHIV who became LFU, MIS 2, MIS 3 and opted out, out of those initiated on ART in FY	107	6	6	228	21	9	306	35	11	368	41	11		
3	PLHIV who died out of those initiated on ART in FY	107	0	0	228	2	1	306	7	2	368	10	3		
4	PLHIV on MMD (3 Months) out of alive on ART at the end of the reporting quarter	1457	51	4	1548	18	1	1584	17	1	1625	18	1		
5	PLHIV on ART retained at the end of the reporting quarter	1688	1457	86	1769	1548	88	1776	1584	89	1827	1625	89		
6	PLHIV who are reported MIS 2, MIS 3, LFU and opted out during the reporting quarter.	1688	280	17	1769	299	17	1776	325	18	1827	336	18		

Analysis of Results:

The performance of private sector ART Centres in New Delhi has not shown improvement over the duration of the study. Over 18% of HIV/AIDS patients registered with the two 2 ART Centres, discontinued Anti-Retroviral Therapy, after the first quarter. Only 25% of the registered HIV/AIDS patients, continued Anti-Retroviral Therapy beyond 6 months.

However, above 91% patients who continued ART, have shown suppressed Viral Load.

*****Patients with suppressed Viral Load are not carriers.***

SWOT Analysis

Strengths – MoHFW guidelines mandate all Private Medical Colleges to set up ART Centres. Drugs are provided for free, by NACO.

Weaknesses – Lack of adherence to NACO guidelines in private sector ART Centres, and inadequate infrastructure.

Opportunities – Patients who are sceptical about visiting government ART Centres, can visit private sector facilities if confidentiality is ensured.

Threats – No incentive for Private Medical Colleges, for compliance with NACO guidelines.

Suggestions – Regular communication with the State AIDS Control Society (SACS), to ensure timely follow-up.

– Mass awareness campaign on the benefits and importance of Anti-Retroviral Therapy.